Pharmaceutical Company Defense

With 125 attorneys in Pharmaceutical & Medical Device Group at Shook, Hardy & Bacon L.L.P. (SHB), the combined experience of this skilled group is extraordinary—and that’s exactly what you need when you are looking for the best pharmaceutical company defense possible.

Just one of our attorneys in this group has more than two decades of experience in pharmaceutical company defense. She has handled cases involving a variety of pharmaceuticals and dietary supplements, including diet drugs, hormone therapies, contraceptives, immunosuppressants, smoking cessation and obesity therapies, allergy medications, anti-depressants, and anti-inflammatories, and drug discovery issues. Her medical device experience includes heart valves, neurovascular coils, orthopedic products, CT scan injectors, surgical instruments and solutions, tracheotomy tubes, intraocular lenses, respiratory protective devices and several chemicals. Her trial experience includes the defense of medical device and drug design, chemical exposure, breach of contract involving the divestiture of product lines, research agreements, distributor agreements and environmental remediation agreements.

Considering we take the team approach—and that just one of our attorneys has this much experience--why would you trust your pharmaceutical company defense to anyone else?

Our pharmaceutical company defense team stays abreast of the latest pharmaceutical and medical device decisions and developments by receiving frequent alerts on the latest industry news, legal developments and regulatory changes affecting both the international and domestic markets. But, we just don’t read about groundbreaking decisions, we are part of them with our innovative defense strategies. Members of our pharmaceutical company defense team have co-authored an article on drug and medical device preemption in the July 2009 Journal of the Kansas Association for Justice. Titled “Drug Preemption v. Medical Device Preemption: A Study in Contrast,” the article addresses two U.S. Supreme Court cases, Wyeth v. Levine and Riegel v. Medtronic, that suggest the law governing preemption may apply differently “depending on whether the product is a drug or a Class III medical device.” The authors also note the developments in recent legislative action seeking to reconcile these differences. “Currently, however, the law governing the two is markedly different in ways that may seem counterintuitive to the unwary,” they conclude, adding that the “prudent practitioner” will take steps to “evaluate preemption issues early and carefully in such cases.”

SHB has more resources and more integrity than any other law firm around. To learn more about our approach to pharmaceutical company defense, contact us today.